![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: HLA-DRA |
Gene summary for HLA-DRA |
![]() |
Gene information | Species | Human | Gene symbol | HLA-DRA | Gene ID | 3122 |
Gene name | major histocompatibility complex, class II, DR alpha | |
Gene Alias | HLA-DRA1 | |
Cytomap | 6p21.32 | |
Gene Type | protein-coding | GO ID | GO:0001775 | UniProtAcc | A0A0G2JMH6 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
3122 | HLA-DRA | GSM4909281 | Human | Breast | IDC | 3.12e-04 | 4.46e-01 | 0.21 |
3122 | HLA-DRA | GSM4909282 | Human | Breast | IDC | 3.41e-12 | 5.27e-01 | -0.0288 |
3122 | HLA-DRA | GSM4909285 | Human | Breast | IDC | 1.52e-05 | -2.54e-01 | 0.21 |
3122 | HLA-DRA | GSM4909286 | Human | Breast | IDC | 6.38e-07 | -2.82e-01 | 0.1081 |
3122 | HLA-DRA | GSM4909287 | Human | Breast | IDC | 2.10e-20 | 8.45e-01 | 0.2057 |
3122 | HLA-DRA | GSM4909290 | Human | Breast | IDC | 6.51e-08 | 5.60e-01 | 0.2096 |
3122 | HLA-DRA | GSM4909293 | Human | Breast | IDC | 9.84e-25 | 7.72e-01 | 0.1581 |
3122 | HLA-DRA | GSM4909300 | Human | Breast | IDC | 5.51e-14 | 8.37e-01 | 0.0334 |
3122 | HLA-DRA | GSM4909305 | Human | Breast | IDC | 2.30e-12 | 6.27e-01 | 0.0436 |
3122 | HLA-DRA | GSM4909311 | Human | Breast | IDC | 1.11e-03 | -1.91e-01 | 0.1534 |
3122 | HLA-DRA | GSM4909312 | Human | Breast | IDC | 1.34e-05 | -2.57e-01 | 0.1552 |
3122 | HLA-DRA | GSM4909315 | Human | Breast | IDC | 2.39e-03 | -2.44e-01 | 0.21 |
3122 | HLA-DRA | GSM4909319 | Human | Breast | IDC | 1.10e-05 | 7.27e-02 | 0.1563 |
3122 | HLA-DRA | brca10 | Human | Breast | Precancer | 1.01e-03 | -2.44e-01 | -0.0029 |
3122 | HLA-DRA | M1 | Human | Breast | IDC | 8.06e-09 | 6.39e-01 | 0.1577 |
3122 | HLA-DRA | M2 | Human | Breast | IDC | 1.96e-05 | 7.93e-01 | 0.21 |
3122 | HLA-DRA | NCCBC11 | Human | Breast | DCIS | 1.46e-09 | 8.53e-01 | 0.1232 |
3122 | HLA-DRA | NCCBC14 | Human | Breast | DCIS | 1.26e-12 | 7.47e-01 | 0.2021 |
3122 | HLA-DRA | NCCBC3 | Human | Breast | DCIS | 2.09e-78 | 1.57e+00 | 0.1198 |
3122 | HLA-DRA | NCCBC5 | Human | Breast | DCIS | 3.23e-35 | 1.17e+00 | 0.2046 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00457859 | Breast | Precancer | positive regulation of cell adhesion | 52/1080 | 437/18723 | 5.74e-07 | 2.49e-05 | 52 |
GO:00024839 | Breast | Precancer | antigen processing and presentation of endogenous peptide antigen | 8/1080 | 19/18723 | 5.10e-06 | 1.53e-04 | 8 |
GO:00198839 | Breast | Precancer | antigen processing and presentation of endogenous antigen | 9/1080 | 26/18723 | 8.75e-06 | 2.34e-04 | 9 |
GO:00421107 | Breast | Precancer | T cell activation | 52/1080 | 487/18723 | 1.37e-05 | 3.42e-04 | 52 |
GO:00508707 | Breast | Precancer | positive regulation of T cell activation | 29/1080 | 216/18723 | 1.94e-05 | 4.58e-04 | 29 |
GO:19037069 | Breast | Precancer | regulation of hemopoiesis | 41/1080 | 367/18723 | 3.95e-05 | 8.52e-04 | 41 |
GO:19030396 | Breast | Precancer | positive regulation of leukocyte cell-cell adhesion | 30/1080 | 239/18723 | 5.13e-05 | 1.07e-03 | 30 |
GO:00027117 | Breast | Precancer | positive regulation of T cell mediated immunity | 12/1080 | 56/18723 | 6.72e-05 | 1.35e-03 | 12 |
GO:00508637 | Breast | Precancer | regulation of T cell activation | 37/1080 | 329/18723 | 8.04e-05 | 1.56e-03 | 37 |
GO:00224098 | Breast | Precancer | positive regulation of cell-cell adhesion | 33/1080 | 284/18723 | 1.03e-04 | 1.89e-03 | 33 |
GO:00071597 | Breast | Precancer | leukocyte cell-cell adhesion | 40/1080 | 371/18723 | 1.07e-04 | 1.94e-03 | 40 |
GO:19021055 | Breast | Precancer | regulation of leukocyte differentiation | 32/1080 | 279/18723 | 1.66e-04 | 2.74e-03 | 32 |
GO:00019168 | Breast | Precancer | positive regulation of T cell mediated cytotoxicity | 8/1080 | 29/18723 | 1.73e-04 | 2.83e-03 | 8 |
GO:00480029 | Breast | Precancer | antigen processing and presentation of peptide antigen | 12/1080 | 62/18723 | 1.89e-04 | 3.04e-03 | 12 |
GO:00224079 | Breast | Precancer | regulation of cell-cell adhesion | 45/1080 | 448/18723 | 2.12e-04 | 3.30e-03 | 45 |
GO:19031313 | Breast | Precancer | mononuclear cell differentiation | 43/1080 | 426/18723 | 2.61e-04 | 3.84e-03 | 43 |
GO:19030377 | Breast | Precancer | regulation of leukocyte cell-cell adhesion | 36/1080 | 336/18723 | 2.61e-04 | 3.84e-03 | 36 |
GO:00027094 | Breast | Precancer | regulation of T cell mediated immunity | 13/1080 | 85/18723 | 1.12e-03 | 1.23e-02 | 13 |
GO:00024789 | Breast | Precancer | antigen processing and presentation of exogenous peptide antigen | 8/1080 | 38/18723 | 1.24e-03 | 1.32e-02 | 8 |
GO:00019146 | Breast | Precancer | regulation of T cell mediated cytotoxicity | 8/1080 | 39/18723 | 1.48e-03 | 1.53e-02 | 8 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa05416113 | Oral cavity | OSCC | Viral myocarditis | 39/3704 | 60/8465 | 7.13e-04 | 2.09e-03 | 1.07e-03 | 39 |
hsa0532319 | Oral cavity | OSCC | Rheumatoid arthritis | 56/3704 | 93/8465 | 9.72e-04 | 2.76e-03 | 1.40e-03 | 56 |
hsa04612113 | Oral cavity | OSCC | Antigen processing and presentation | 47/3704 | 78/8465 | 2.37e-03 | 6.35e-03 | 3.23e-03 | 47 |
hsa0465811 | Oral cavity | OSCC | Th1 and Th2 cell differentiation | 53/3704 | 92/8465 | 5.00e-03 | 1.20e-02 | 6.13e-03 | 53 |
hsa0516929 | Oral cavity | LP | Epstein-Barr virus infection | 106/2418 | 202/8465 | 4.30e-13 | 9.54e-12 | 6.15e-12 | 106 |
hsa05166210 | Oral cavity | LP | Human T-cell leukemia virus 1 infection | 100/2418 | 222/8465 | 8.94e-08 | 1.29e-06 | 8.35e-07 | 100 |
hsa0414529 | Oral cavity | LP | Phagosome | 73/2418 | 152/8465 | 2.37e-07 | 3.29e-06 | 2.12e-06 | 73 |
hsa0516424 | Oral cavity | LP | Influenza A | 80/2418 | 171/8465 | 2.56e-07 | 3.41e-06 | 2.20e-06 | 80 |
hsa05416210 | Oral cavity | LP | Viral myocarditis | 32/2418 | 60/8465 | 4.55e-05 | 2.91e-04 | 1.88e-04 | 32 |
hsa0514524 | Oral cavity | LP | Toxoplasmosis | 51/2418 | 112/8465 | 8.99e-05 | 5.54e-04 | 3.57e-04 | 51 |
hsa04612210 | Oral cavity | LP | Antigen processing and presentation | 37/2418 | 78/8465 | 2.98e-04 | 1.60e-03 | 1.03e-03 | 37 |
hsa0515221 | Oral cavity | LP | Tuberculosis | 65/2418 | 180/8465 | 1.60e-02 | 4.92e-02 | 3.17e-02 | 65 |
hsa0516936 | Oral cavity | LP | Epstein-Barr virus infection | 106/2418 | 202/8465 | 4.30e-13 | 9.54e-12 | 6.15e-12 | 106 |
hsa0516638 | Oral cavity | LP | Human T-cell leukemia virus 1 infection | 100/2418 | 222/8465 | 8.94e-08 | 1.29e-06 | 8.35e-07 | 100 |
hsa0414536 | Oral cavity | LP | Phagosome | 73/2418 | 152/8465 | 2.37e-07 | 3.29e-06 | 2.12e-06 | 73 |
hsa0516434 | Oral cavity | LP | Influenza A | 80/2418 | 171/8465 | 2.56e-07 | 3.41e-06 | 2.20e-06 | 80 |
hsa0541637 | Oral cavity | LP | Viral myocarditis | 32/2418 | 60/8465 | 4.55e-05 | 2.91e-04 | 1.88e-04 | 32 |
hsa0514534 | Oral cavity | LP | Toxoplasmosis | 51/2418 | 112/8465 | 8.99e-05 | 5.54e-04 | 3.57e-04 | 51 |
hsa0461237 | Oral cavity | LP | Antigen processing and presentation | 37/2418 | 78/8465 | 2.98e-04 | 1.60e-03 | 1.03e-03 | 37 |
hsa0515231 | Oral cavity | LP | Tuberculosis | 65/2418 | 180/8465 | 1.60e-02 | 4.92e-02 | 3.17e-02 | 65 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
HLA-DRA | CD4 | HLA-DRA_CD4 | MHC-II | Breast | DCIS |
HLA-DRA | CD4 | HLA-DRA_CD4 | MHC-II | Breast | Healthy |
HLA-DRA | CD4 | HLA-DRA_CD4 | MHC-II | Breast | IDC |
HLA-DRA | CD4 | HLA-DRA_CD4 | MHC-II | Cervix | ADJ |
HLA-DRA | CD4 | HLA-DRA_CD4 | MHC-II | Cervix | CC |
HLA-DRA | CD4 | HLA-DRA_CD4 | MHC-II | Cervix | Healthy |
HLA-DRA | CD4 | HLA-DRA_CD4 | MHC-II | Cervix | Precancer |
HLA-DRA | CD4 | HLA-DRA_CD4 | MHC-II | CRC | AD |
HLA-DRA | CD4 | HLA-DRA_CD4 | MHC-II | CRC | ADJ |
HLA-DRA | CD4 | HLA-DRA_CD4 | MHC-II | CRC | FAP |
HLA-DRA | CD4 | HLA-DRA_CD4 | MHC-II | CRC | MSI-H |
HLA-DRA | CD4 | HLA-DRA_CD4 | MHC-II | CRC | MSS |
HLA-DRA | CD4 | HLA-DRA_CD4 | MHC-II | CRC | SER |
HLA-DRA | CD4 | HLA-DRA_CD4 | MHC-II | Endometrium | ADJ |
HLA-DRA | CD4 | HLA-DRA_CD4 | MHC-II | Endometrium | AEH |
HLA-DRA | CD4 | HLA-DRA_CD4 | MHC-II | Endometrium | EEC |
HLA-DRA | CD4 | HLA-DRA_CD4 | MHC-II | Endometrium | Healthy |
HLA-DRA | CD4 | HLA-DRA_CD4 | MHC-II | HNSCC | ADJ |
HLA-DRA | CD4 | HLA-DRA_CD4 | MHC-II | HNSCC | Healthy |
HLA-DRA | CD4 | HLA-DRA_CD4 | MHC-II | HNSCC | Precancer |
Page: 1 2 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
HLA-DRA | SNV | Missense_Mutation | novel | c.136G>A | p.Glu46Lys | p.E46K | P01903 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
HLA-DRA | SNV | Missense_Mutation | c.595N>A | p.Leu199Ile | p.L199I | P01903 | protein_coding | deleterious(0.03) | benign(0.017) | TCGA-EK-A2PI-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD | |
HLA-DRA | SNV | Missense_Mutation | c.607T>C | p.Trp203Arg | p.W203R | P01903 | protein_coding | deleterious(0.01) | possibly_damaging(0.459) | TCGA-A6-5665-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
HLA-DRA | SNV | Missense_Mutation | c.176N>C | p.Val59Ala | p.V59A | P01903 | protein_coding | deleterious(0.01) | probably_damaging(0.925) | TCGA-A6-6141-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | 5-fu | SD | |
HLA-DRA | SNV | Missense_Mutation | rs751526731 | c.205N>T | p.Arg69Trp | p.R69W | P01903 | protein_coding | tolerated(0.09) | probably_damaging(1) | TCGA-A6-6142-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | fluorouracil | PD |
HLA-DRA | SNV | Missense_Mutation | c.695N>C | p.Ile232Thr | p.I232T | P01903 | protein_coding | tolerated(0.06) | benign(0.043) | TCGA-AA-3495-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
HLA-DRA | SNV | Missense_Mutation | c.748N>T | p.Arg250Cys | p.R250C | P01903 | protein_coding | tolerated(0.23) | benign(0.031) | TCGA-AA-3511-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | PD | |
HLA-DRA | SNV | Missense_Mutation | c.385N>A | p.Val129Ile | p.V129I | P01903 | protein_coding | tolerated(1) | benign(0) | TCGA-AA-3864-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
HLA-DRA | SNV | Missense_Mutation | c.371N>C | p.Leu124Pro | p.L124P | P01903 | protein_coding | deleterious(0.02) | benign(0.149) | TCGA-D5-6927-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
HLA-DRA | SNV | Missense_Mutation | c.97A>G | p.Ile33Val | p.I33V | P01903 | protein_coding | tolerated(0.28) | benign(0.353) | TCGA-NH-A5IV-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
3122 | HLA-DRA | DRUGGABLE GENOME, CELL SURFACE, CLINICALLY ACTIONABLE | amoxicillin | AMOXICILLIN | 30664875 | |
3122 | HLA-DRA | DRUGGABLE GENOME, CELL SURFACE, CLINICALLY ACTIONABLE | NIVOLUMAB | NIVOLUMAB | 26822383 | |
3122 | HLA-DRA | DRUGGABLE GENOME, CELL SURFACE, CLINICALLY ACTIONABLE | PEMBROLIZUMAB | PEMBROLIZUMAB | 26822383 | |
3122 | HLA-DRA | DRUGGABLE GENOME, CELL SURFACE, CLINICALLY ACTIONABLE | clavulanate | CLAVULANIC ACID | 30664875 | |
3122 | HLA-DRA | DRUGGABLE GENOME, CELL SURFACE, CLINICALLY ACTIONABLE | ATEZOLIZUMAB | ATEZOLIZUMAB | 26822383 | |
3122 | HLA-DRA | DRUGGABLE GENOME, CELL SURFACE, CLINICALLY ACTIONABLE | flucloxacillin | FLOXACILLIN | 30664875 |
Page: 1 |